Phys Written Answers · respiratory
Pulmonary Embolism — Written Clinical Reasoning
DCE long-case preparation: structured written reasoning for pulmonary embolism, including diagnostic algorithm application (Wells, D-dimer, CTPA/VQ), risk stratification (sPESI, biomarkers, echo), and integrated management planning (anticoagulation, reperfusion, duration).
On this page
Study tools
Target exams
SAQ 1 — Diagnostic reasoning and risk stratification (10 marks, 30 minutes)
Prompt: Walk through the diagnostic algorithm you applied, the role of the D-dimer in this patient, and the risk stratification that determines your level of monitoring. [1]
Model answer
Pre-test probability and imaging pathway (4 marks): [1]
This woman has a Wells score of 7.5, which places her in the PE-likely category (greater than 4). In a PE-likely patient, the correct next step is CT pulmonary angiography directly — a D-dimer has no role here, because even a negative high-sensitivity D-dimer does not have a sufficiently low likelihood ratio to exclude PE at high pre-test probability, and a positive result would simply prompt the CTPA anyway. The CTPA confirmed a large central pulmonary embolus with right ventricular strain, consistent with her presentation. [1]
Examiner point: The two-tier Wells score (PE likely greater than 4, PE unlikely 4 or less) was established by Wells et al. (Ann Intern Med 2001). Committing to a structured pre-test probability before testing is mandatory — every subsequent test interpretation depends on it. [1]
Why D-dimer was bypassed (2 marks): [1]
D-dimer is a rule-OUT test only. It is highly sensitive and poorly specific. Its role is to safely exclude PE in a PE-unlikely patient. In a PE-likely patient, the post-test probability after a negative D-dimer remains above the treatment threshold, so imaging is required regardless. In older patients where a D-dimer IS being used, the age-adjusted cutoff (age multiplied by 10 micrograms/L for age over 50) safely increases the exclusion rate, as shown by ADJUST-PE (Righini et al., JAMA 2014). [1]
Risk stratification — she is intermediate-high risk (4 marks): [1]
Although she was briefly hypotensive (96 systolic) on arrival, she is now normotensive, which moves her out of the high-risk category. She is, however, intermediate-HIGH risk by the ESC framework: she has right ventricular dysfunction on echo (dilation with septal flattening) AND a positive biomarker (troponin 0.06). Her sPESI is at least 1 (pulse 114, saturation under 95 percent, recent surgery), confirming she is not low-risk and requires inpatient admission. [1]
The implication: she needs continuous cardiac monitoring, serial troput measurements, and a low threshold for rescue thrombolysis if she decompensates. She should NOT receive prophylactic (upfront) systemic thrombolysis — the PEITHO trial (Meyer et al., NEJM 2014) showed that tenecteplase in intermediate-risk PE reduced the composite of death or decompensation but at the cost of significantly increased major bleeding and an intracranial haemorrhage rate of around 2 percent. Prophylactic lysis is reserved for high-risk (massive) PE. [1]
References5ShowHide
- [1]Wells PS, Anderson DR, Rodger M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer Ann Intern Med, 2001.PMID 11453709
- [2]Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study JAMA, 2014.PMID 24643601
- [3]Dittmer DP An appraisal of non-AIDS-defining cancers: comment on Spectrum of cancer risk late after AIDS onset in the United States Arch Intern Med, 2010.PMID 20696959
- [4]Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism N Engl J Med, 2014.PMID 24716681
- [5]Johnson SR, Cooper MN, Davis EA, et al. Hypoglycaemia, fear of hypoglycaemia and quality of life in children with Type 1 diabetes and their parents Diabet Med, 2013.PMID 23808967